This approach was used by Avidity Biosciences, Inc, which is applying a conjugate of specific antibodies that bind to the transferrin receptor 1 and a small interfering RNA, targeting DMPK mRNA (AOC 1001) in the Phase 1⁄2 MARINA trial for the treatment of patients with adult DM1 (Table 1). This evidence concerns the gene DMPK and myotonic dystrophy type 1.